What's Hot
View all perspectives
Dr. Rachel Tate uptoTate
2 years 5 months ago
Female PsA patients on TNFi have reduced treatment effectiveness, LDA (vs males). #EULAR2022 POS0077 @RheumNow https://t.co/EwDwxUarNb https://t.co/W5xgQlrnlF
David Liew drdavidliew
2 years 5 months ago
Hilarious debate #EULAR2022 between Christian Dejaco and Robert Landewe on whether telemedicine is the future of rheumatology. In amongst the trash talking, here are some highlights @RheumNow
Janet Pope Janetbirdope
2 years 5 months ago
#ClinicalPearl. Why do doctors prescribe #JAKi in RA? Efficacy, fast onset, X-ray inhibition, can work as monotherapy, remission - in order of diminishing frequency BUT I will add access and oral (convenience). POS0680 @RheumNow @eular_org #EULAR2022 https://t.co/XHtNqguqvh
Eric Dein ericdeinmd
2 years 5 months ago
#EULAR2022 Telemedicine: PROs
💻Triage, reduce wait time, direct other specialty referral
💻High agreement w F2F evaluation (79-97%)
💻Saves resources, react quickly to minor flare
💻Better adherence
@RheumNow
Janet Pope Janetbirdope
2 years 5 months ago
BTKi are they effective in #rheumatology? Seem to work in preclinical models of inflammation but so far clinical results seem disappointing #POS0397 @RheumNow @eular_org #EULAR2022 https://t.co/2NjcMnU1d6
Eric Dein ericdeinmd
2 years 5 months ago
#EULAR2022
R Landewe: Anti-Telemedicine
🩺Rheumatology about long-term relationship & communication
🩺"Telemedicine impoverishes visit" by only exchanging information
@Rheumnow
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 5 months ago
#POS0752 #EULAR2022 Is there difference btw childhood- vs adult-onset #lupus?A cohort study of claims database >10,000 pts showed:
Children had higher activity & more likely to receive immunosuppressant
Some activities persisted
Useful to bear in transition clinic @RheumNow https://t.co/KVHZUgAOlV
Robert B Chao, MD doctorRBC
2 years 5 months ago
Inflammation (ESR >20 and cardiovascular risk scores) in AxSpA pts associated with incident hypertension.
csDMARD may be associated with HTN
NSAID and biologics not associated with incident HTN
@RheumNow #EULAR2022 ABST#POS0154 https://t.co/5pYjXrpCec
TheDaoIndex KDAO2011
2 years 5 months ago
#PEARLS by EULAR President Prof Iagnocco:
1. Enthesitis can be present in 25% of #SLE patients
2. Erosions can be common and independent of ACPA/RF status
3. Active myositis is indistinguishable from IIM
4. Don't forget pain osteonecrosis/osteomyelitis #EULAR2022 @rheumnow https://t.co/8uWCw9rEve
Md Yuzaiful Md Yusof Yuz6Yusof
2 years 5 months ago
#OP0249 #EULAR2022 Dr Machado presented pooled data >5000 pts. Poor #COVID outcomes in Pso, PsA and AxSpa were associated with the usual suspects: Age, male, high disease activity and comorbidities. No specific bDMARDs was associated. Good news for our patients @RheumNow https://t.co/itzmwqKCrH
TheDaoIndex KDAO2011
2 years 5 months ago
Staggering facts by Prof Vital on #SLE and SkM Sx’s:
- 50% of first Sx’s is SkM
- SkM Sx are in top 3 concerns for pts
- 34% pts w/SkM Sx stopped working median 4 yrs
- SkM damage clusters with CVD damage
#EULAR2022 @rheumnow https://t.co/NXEW3XYCQZ
Aurelie Najm AurelieRheumo
2 years 5 months ago
📲The great debate on Telemedicine 💻
R. Landewe warns us against "check box medicine" and its consequences on AxSpA overdiagnosis.
@RheumNow #EULAR2022 https://t.co/Xwg0aAdHwE
TheDaoIndex KDAO2011
2 years 5 months ago
“#SLEDAI should be scored when there is joint swelling (not just tenderness)—note that only 48% of pts with tenderness will have u/s evidence of inflammation” – Prof E Vital #EULAR2022 @rheumnow https://t.co/hhsZ9wMAWs
Robert B Chao, MD doctorRBC
2 years 5 months ago
Ok to taper?
In PsA and AxSpA pts on TNFi, a T2T w/ tapering strategy was non-inferior to a T2T w/o tapering.
69% of tapered group remained in LDA, 73% no-taper group in LDA after 12 months.
Taper group did use more NSAIDs, cDMARDs, steroids
@RheumNow #EULAR2022 ABST#OP0261
Janet Pope Janetbirdope
2 years 5 months ago
JAK will quiet Still’s disease? 7 w Still’s 4 refractory disease had benefit w #JAKi POS0014. Needs more data but looks promising most w partial response . 5 on #Tofacitinib and 2 w #Baricitinib. @eular_org #EULAR2022 POS0014 @RheumNow https://t.co/j9IRgT9XJf
Poster Hall